SCHEDULE 13G/A: Stonepine Capital Entities Disclose 5.1% Stake in Aprea Therapeutics

Stonepine Capital Management, LLC and its affiliates have filed an amended Schedule 13G, disclosing a 5.1% beneficial ownership stake in Aprea Therapeutics, Inc. as of December 31, 2024.

Summary

• Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico collectively reported beneficial ownership of 286,395 shares of Aprea Therapeutics, Inc. Common Stock.
• This ownership represents 5.1% of Aprea Therapeutics' outstanding Common Stock.
• The 5.1% stake is calculated based on 149,221 shares of Common Stock directly owned and 137,174 shares underlying warrants, relative to 5,434,903 shares of Common Stock outstanding as of November 7, 2024.
• The reporting persons share both voting and dispositive power over all 286,395 beneficially owned shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Aprea Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects. It reflects a passive investment stake.

Positives

• Indicates continued investment and confidence from Stonepine Capital entities in Aprea Therapeutics, Inc.
• The stake is held for investment purposes in the ordinary course of business, suggesting a passive, long-term interest rather than an activist intent.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing is a standard disclosure of a passive investment stake by an institutional investor and does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.

Key Dates

Keywords

Aprea Therapeutics, Stonepine Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment, SEC Filing, Biotechnology, Pharmaceuticals, APRE